Repligen Corp. (RGEN)

166.82 +0.40 (+0.24%) USD  |  NASDAQ  |  Jan 09, 16:00
166.55 -0.27 (-0.16%) After-Hours: 20:00
More

Repligen Research and Development Expense (% of Annual Revenues)

Research and Development Expense (% of Annual Revenues) Chart

View Research and Development Expense (% of Annual Revenues) for RGEN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (% of Annual Revenues) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (% of Annual Revenues) Range, Past 5 Years

View Research and Development Expense (% of Annual Revenues) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (% of Annual Revenues) Benchmarks

View Research and Development Expense (% of Annual Revenues) Benchmarks
Start Trial
Enovis Corp. Upgrade
Perspective Therapeutics, Inc. Upgrade
InfuSystem Holdings, Inc. --
Xtant Medical Holdings, Inc. Upgrade
VolitionRX Ltd. Upgrade